NICE approval for denosumab in cancer

The osteoclast-targeting antibody denosumab has been accepted for NHS use in patients with bone metastases.

by
Denosumab targets the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts
Denosumab targets the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package